Dr. Uusinarkaus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
41 State Highway 67
Woodland Park, CO 80863Phone+1 719-687-8550Fax+1 719-687-8919
Summary
- Dr. Uusinarkaus is involved in medical education – he is an assistant professor of Family Medicine at the University of Colorado, Denver. He also has a passion for preventive cardiology, becoming certified in Clinical Lipidology the first year it was offered, in 2005. He has additional training as a specialist in the treatment of hypertension.
He is currently a board member of the South West Lipid Association – a regional entity of the National Lipid Association. In addition, he maintains an active research interest, participating as a Principal Investigator in many clinical trials involving new treatments for common ailments and diseases.
Education & Training
Christ Hospital/University of Cincinnati College of MedicineResidency, Family Medicine, 1994 - 1997
Loma Linda University School of MedicineClass of 1994
Certifications & Licensure
CO State Medical License 2001 - 2025
OH State Medical License 1995 - 2003- American Board of Family Medicine Family Medicine
- American Board of Obesity Medicine Obesity Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2012
- Fellow (FAAFP) American Academy of Family Physicians, 2010
Clinical Trials
- Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
- Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL Start of enrollment: 2017 Apr 06
Publications & Presentations
PubMed
- 19 citationsThe Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase I...Kenneth E. Schmader, Myron J. Levin, Katrijn Grupping, Sean Matthews, David Butuk
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2019-07-12 - 11 citationsImproved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.Johan Jendle, Andreas L. Birkenfeld, William H. Polonsky, Robert Silver, Kari Uusinarkaus
Diabetes, Obesity & Metabolism. 2019-10-01
Journal Articles
- The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults: An Open Phase III TrialMyron J Levin, David Butuk, Kenneth E Schmader, Charles Fogarty, Paul Hartley, Max Nevarez, Nicola P Klein, Kari Uusinarkaus, The Journals of Gerontology
Press Mentions
When Goals Are Not Met in Diabetes CareDecember 11th, 2017
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
